Mode
Text Size
Log in / Sign up
Phase 1 Completed N=60 Randomized Single-blind Other

Study to Investigate the Pharmacokinetic Profile

Healthy Male Subjects
Source: ClinicalTrials.gov NCT03286829 ↗
Enrolled (actual)
60
Serious AEs
0.0%
Results posted
May 2020
Primary outcomePrimary: AUC0-48 — 32.06; 6.491; 45.89; 30.14 ng*hr/mL

Summary

A randomized, open-label, single-dose, parallel-arm, Phase 1 study to investigate the pharmacokinetic profile of a fixed-dose combination tablet of tesofensine and metoprolol (Tesomet) and co-administration of tesofensine plus commercial metoprolol in adult healthy subjects

Outcome Measures

OutcomeResultp-value
PRIMARY
AUC0-48
32.06; 6.491; 45.89; 30.14
SECONDARY
Cmax
0.9528; 0.1934; 1.357; 0.8085
SECONDARY
Tmax
6.12; 6.00; 6.00; 8.00

Eligibility Criteria

Inclusion Criteria

  • Subject voluntarily agrees to participate in this study and signs an Independent Ethics Committee (IEC)-approved informed consent prior to performing any of the Screening Visit procedures.
  • Males between 18 to 55 years of age, inclusive, at the Screening Visit.
  • Nonsmokers (or other nicotine use) as determined by history (no nicotine use over the past 6 months) and by urine cotinine concentration (< 500 ng/mL) at the Screening Visit and admission.
  • BMI between 18.5 and 30.0 kg/m2, inclusive, at the Screening Visit.
  • Healthy, determined by pre-study medical evaluation (medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory evaluations).

Exclusion Criteria

  • Subject has history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy as judged by the Investigator.
  • Subject has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Subject has history of alcohol and/or illicit drug abuse within 2 years of entry.
  • Subject is unwilling to avoid consumption of coffee and caffeine-containing beverages within 48 hours prior to admission until discharge from the clinical site.
  • Subject is unwilling to avoid use of alcohol or alcohol-containing foods, medications or beverages, within 48 hours prior to admission until discharge from the clinical site.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03286829). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search